Citations

Clear

6273 citation(s) found for "To, Andrew".

Energy Expenditure and Intensity Levels During a 6170-m Summit in the Karakoram Mountains
Taylor, Bryan J. , Johnson, Bruce D. , Miller, Andrew David , Taylor, Bryan J

Mayo Clinic

Wilderness & Environmental Medicine | September 13, 2013 | Volume: 24 | Issue: 4 | Pages: 337-344

10.1016/j.wem.2013.06.009 | PMID 24041623 Get It

Objective Although the majority of high altitude studies have used doubly labeled water to assess energy expenditure (EE), minimal research has examined variation in intensity levels while participating in such an expedition. The purpose of this study was to use ambulatory monitoring technology to assess EE and time spent in moderate (3.0–6.0 METS), vigorous (6.0–9.0 METS), and very vigorous (>9.0 METS) intensities during an expedition to summit a 6170-m peak in Northern Pakistan. Methods Twelve men and 2 women were studied. Their EE was determined from galvanic skin response, heat flux, and biaxial accelerometry using a multisensor armband. Lake Louise Scores for altitude illness assessment were obtained each morning. Results Average daily total EE and number of steps taken was 4173 ± 848 kcal/d (range, 3332 to 4838 kcal/d) and 26,232 ± 7210 steps/d (range, 11,788 to 34,979 steps/d), respectively. On average, subjects spent approximately 7.7 h/d performing physical activity (>3.0 METS). Of this, subjects spent 399 ± 107, 61 ± 77, and 3 ± 10 min/d at moderate, vigorous, and very vigorous intensity levels, respectively, corresponding to 88%, 11%, and 1% of total physical activity time. During summit day, subjects climbed at an intensity equivalent to approximately 42% of their high altitude predicted maximal oxygen consumption at 5100 m). Conclusions During a high altitude expedition, subjects predominantly exercise at a moderate intensity, with limited time spent at higher intensity levels. Use of accelerometer-based technology may provide more cost-effective and logistically easier means of assessing EE in extreme environments.
The effect of low‐ and high‐velocity tendon excursion on the mechanical properties of human cadaver subsynovial connective tissue
Filius, Anika , Thoreson, Andrew R. , Yang, Tai‐Hua , Vanhees, Matthias , An, Kai‐Nan, Zhao, Chunfeng , Amadio, Peter C. , An, Kai‐Nan

Mayo Clinic

Journal of Orthopaedic Research | September 13, 2013 | Volume: 32 | Issue: 1 | Pages: 123-128

10.1002/jor.22489 | PMID 24038298 Get It

SUMMARYFibrosis of the subsynovial connective tissue (SSCT) in the carpal tunnel is the most common histological finding in carpal tunnel syndrome (CTS). Fibrosis may result from damaged SSCT. Previous studies found that with low‐velocity (2 mm/s), tendon excursions can irreversibly damage the SSCT. We investigated the effect of tendon excursion velocity in the generation of SSCT damage. Nine human cadaver wrists were used. Three repeated cycles of ramp‐stretch testing were performed simulating 40%, 60%, 90%, and 120% of the middle finger flexor tendon superficialis physiological excursion with an excursion velocity of 60 mm/s. Energy and force were calculated and normalized by values obtained in the first cycle for each excursion level. Data were compared with low‐velocity excursion data. For high‐velocity excursions, a significant drop in the excursion energy ratio was first observed at an excursion level of 60% physiological excursion (p < 0.024) and that for low‐velocity excursions was first observed at 90% physiological excursion (p < 0.038). Furthermore, the energy ratio was lower at 60% for high velocities (p ≤ 0.039). Increasing velocity lowers the SSCT damage threshold. This finding may be relevant for understanding the pathogenesis of SSCT fibrosis, such as that accompanying CTS, and a relationship with occupational factors. © 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:123–128, 2014.
Fibrosarcoma: a review and update
Folpe, Andrew L.

Mayo Clinic

Histopathology | September 12, 2013 | Volume: 64 | Issue: 1 | Pages: 12-25

10.1111/his.12282 | PMID 24266941 Get It

Adult fibrosarcoma, defined by the World Health Organization as a ‘malignant neoplasm composed of fibroblasts with variable collagen production and, in classical cases, a “herringbone” architecture’, is a very rare soft tissue sarcoma. Once considered the most common adult sarcoma, the incidence of adult fibrosarcoma has declined dramatically over the past several decades. This is due to (i) evolution in the classification of soft tissue tumours (ii) recognition of clinically, morphologically and genetically distinctive subtypes of fibrosarcoma and (iii) increased understanding of the many other mesenchymal and non‐mesenchymal tumours that may mimic fibrosarcoma. This review article will summarize the current state of our knowledge about strictly defined adult fibrosarcoma and discuss important entities in its differential diagnosis, including various fibrosarcoma variants, monophasic synovial sarcoma and other potential mesenchymal and non‐mesenchymal mimics.
Stroke Genetics Network (SiGN) Study
Arnett, Donna K. , Ay, Hakan , Brown, Robert D. , Benavente, Oscar, Bakker, Paul I. W. de , Dichgans, Martin , Doheny, Kimberly F. , Fornage, Myriam , Grewal, Raji P., Gwinn, Katrina , Conde, Jordi Jiménez, Johnson, Julie A. , Laurie, Cathy C. , Lee, Jin‐Moo , Lindgren, Arne, Markus, Hugh S. , McArdle, Patrick F. , McClure, Leslie A. , Mitchell, Braxton D. , Schmidt, Reinhold , Rexrode, Kathryn M. , Rich, Stephen S. , Rothwell, Peter M. , Sacco, Ralph L., Shuldiner, Alan R. , Słowik, Agnieszka , Sudlow, Cathie , Thijs, Vincent , Woo, Daniel , Worrall, Bradford B. , Wu, Ona , Kittner, Steven J. , collaborators, The SiGN study also includes the following, Anderson, Christopher D. , Andrén, Kerstin , Barrett, Kevin M. , Benner, Thomas, Bentley, Paul , Bevan, Steven, Biffi, Alessandro , Chapman, Sherita , Cheng, Yu‐Ching, Delavaran, Hossein , Gamble, Dale M., Giralt, Eva, Grazer, Anja, Gschwendtner, Andreas, Hegge, Caityln, Heitsch, Laura , Helenius, Johanna, Huq, Mohammed Saiful, Irie, Robert E., Jackson, Rebecca D. , Katschnig, Petra , Katsnelson, Michael , Khoury, Naïm , Kilinc, Selma, Kumar, Gyanendra, Langefeld, Carl D. , Lemmens, Robin , Malik, Shaneela , Melander, Olle , Nordström, Sara , Ois, Ángel , Ossi, Raid G., Peddareddygari, Leema Reddy , Pedersén, Annie , Pucek, Mateusz, Redfors, Petra , Rhodes, J. , Saraf, Neha, Schuerks, Markus, Seiler, Stephan , Sheikh, Huma U., Sparks, Mary J., Stoegerer, Eva, Temple, Ella, Valenti, Raffaella , Weir, David R. , Weissman, Darren, Woodfield, Rebecca, Yiin, Gabriel , Soliman, Elsayed Z. , Cushman, Mary , Kumar, Gyanendra , Bevan, Steve , Meschia, James F. , Cole, John W. , Jern, Christina , Jood, Katarina , Lindgren, Arne, Rosand, Jonathan M. , Rundek, Tatjana , Sharma, Pankaj Kumar , Wassertheil-Smoller, Sylvia W , collaborators, The SiGN study also includes the following, Andsberg, Gunnar , Arsava, Ethem Murat , Bevan, Steven, Brenner, David A. , Deline, Chris A. , Dziedzic, Tomasz , Holmegaard, Lukas , Kilinc, Selma, Kumar, Gyanendra, Labovitz, Daniel , Lanfranconi, Silvia , Li, Linxin , Norrving, Bo , Pera, Joanna , Rannikmäe, Kristiina , Ribasés, Marta , Southerland, Andrew M. , Sunyer, Jordi , Dichgans, Martin , Rich, Stephen S , Lemmens, Robin , Mitchell, Braxton D , Shuldiner, Alan R , Arnett, Donna K , Wu, Ona , Lee, Jin-Moo

Mayo Clinic

Stroke | September 11, 2013 | Volume: 44 | Issue: 10 | Pages: 2694-2702

10.1161/strokeaha.113.001857 | PMID 24021684 Get It

Background and Purpose— Meta-analyses of extant genome-wide data illustrate the need to focus on subtypes of ischemic stroke for gene discovery. The National Institute of Neurological Disorders and Stroke SiGN (Stroke Genetics Network) contributes substantially to meta-analyses that focus on specific subtypes of stroke. Methods— The National Institute of Neurological Disorders and Stroke SiGN includes ischemic stroke cases from 24 genetic research centers: 13 from the United States and 11 from Europe. Investigators harmonize ischemic stroke phenotyping using the Web-based causative classification of stroke system, with data entered by trained and certified adjudicators at participating genetic research centers. Through the Center for Inherited Diseases Research, the Network plans to genotype 10 296 carefully phenotyped stroke cases using genome-wide single nucleotide polymorphism arrays and adds to these another 4253 previously genotyped cases, for a total of 14 549 cases. To maximize power for subtype analyses, the study allocates genotyping resources almost exclusively to cases. Publicly available studies provide most of the control genotypes. Center for Inherited Diseases Research–generated genotypes and corresponding phenotypes will be shared with the scientific community through the US National Center for Biotechnology Information database of Genotypes and Phenotypes, and brain MRI studies will be centrally archived. Conclusions— The Stroke Genetics Network, with its emphasis on careful and standardized phenotyping of ischemic stroke and stroke subtypes, provides an unprecedented opportunity to uncover genetic determinants of ischemic stroke.
Minimal effect of bortezomib in reducing anti‐pig antibodies in human leukocyte antigen‐sensitized patients: a pilot study
Bentall, Andrew , Long, Cassandra , Fang, Jason, Andreyev, Oleg , Lunz, John G., Ezzelarab, Mohamed , Abu‐Elmagd, Kareem , Shapiro, Ron , Ayares, David , Stegall, Mark D. , Hara, Hidetaka , Ezzelarab, Mohamed B. , Cooper, David K. C. , Stegall, Mark D , Bentall, Andrew

Mayo Clinic

Xenotransplantation | September 3, 2013 | Volume: 20 | Issue: 6 | Pages: 429-437

10.1111/xen.12052 | PMID 23998233 Get It

AbstractBackgroundBortezomib, a proteasome inhibitor used to treat multiple myeloma, has been administered (± plasma exchange ± intravenous immunoglobulin [IVIg]) in attempts to reduce antibodies against human leukocyte antigens (HLA) in sensitized patients undergoing organ transplantation. To our knowledge, bortezomib has not been investigated for its effect on natural anti‐pig antibodies. If bortezomib could reduce the production of anti‐pig antibodies, this would likely be beneficial to the outcome of pig organ grafts in primates.MethodsNine patients received bortezomib either to reduce anti‐HLA antibody levels before organ allotransplantation or to treat antibody‐mediated rejection. Patients at the Mayo Clinic (Group 1; n = 4) received bortezomib alone, whereas at the UPMC (Group 2; n = 5), this was combined with plasmaphereses ± IVIg in some cases. Anti‐pig IgM and IgG levels against wild‐type (WT) and α1,3‐galactosyltransferase gene knockout (GTKO) pig aortic endothelial cells (flow cytometry—relative mean fluorescence intensity) and anti‐Gal IgM and IgG (ELISA–OD480 nm) were measured pre‐ and post‐bortezomib therapy.ResultsMean anti‐pig IgM levels were 11.2 (WT) and 1.9 (GTKO) pre‐bortezomib treatment and 9.4 (WT: P = 0.02) and 1.7 (GTKO: P = 0.33) post‐bortezomib treatment, respectively. Mean anti‐pig IgG levels were 4.3 (WT) and 1.5 (GTKO) pre‐bortezomib treatment and 3.6 (WT: P = 0.21) and 1.4 (GTKO: P = 0.20) post‐bortezomib treatment, respectively. Mean anti‐Gal IgM and IgG levels were 0.7 and 1.1, respectively, pre‐treatment, and 0.6 (P = 0.03) and 1.1 (NS), respectively, post‐treatment. When the data were analyzed in Groups 1 and 2 separately, there were no significant differences between the pre‐ and post‐bortezomib levels of anti‐pig, anti‐non‐Gal, or anti‐Gal IgM or IgG.ConclusionsFrom this limited study, we conclude that bortezomib might reduce anti‐Gal IgM levels in primates, but, in this respect alone, is unlikely to have any significant effect on the outcome of GTKO pig organ transplantation.
Novel TRAF1‐ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma
Vasmatzis, George , Asmann, Yan W. , Davila, Jaime , Middha, Sumit , Eckloff, Bruce W., Johnson, Sarah H. , Porcher, Julie C., Ansell, Stephen M. , Caride, Ariel J. , Feldman, Andrew L. , Davila, Jaime I

Mayo Clinic

Genes, Chromosomes and Cancer | September 2, 2013 | Volume: 52 | Issue: 11 | Pages: 1097-1102

10.1002/gcc.22104 | PMID 23999969 Get It

Chromosomal translocations leading to expression of abnormal fusion proteins play a major role in the pathogenesis of various hematologic malignancies. The recent development of high‐throughput, “deep” sequencing has allowed discovery of novel translocations leading to a rapid increase in understanding these diseases. Translocations involving the anaplastic lymphoma kinase (ALK) gene leading to ALK fusion proteins originally were discovered in anaplastic large cell lymphomas (ALCLs). Among ALCLs, NPM1‐ALK fusions are most common and lead to nuclear localization of the fusion protein. Here, we present a 50‐year‐old male with ALCL demonstrating cytoplasmic ALK immunoreactivity only, suggesting the presence of a non‐NPM1 fusion partner. We performed deep RNA sequencing of tumor tissue from this patient and identified a novel transcript fusing Exon 6 of TRAF1 to Exon 20 of ALK. The TRAF1‐ALK fusion transcript was confirmed at the mRNA level by Sanger sequencing and the fusion protein was visualized by Western blot. The discovery of this TRAF1‐ALK fusion expands the diversity of known ALK fusion partners and highlights the power of deep sequencing for fusion transcript discovery. © 2013 Wiley Periodicals, Inc.
Repairing Damaged Tendon and Muscle: Are Mesenchymal Stem cells and Scaffolds the Answer?
Davies, Benjamin M. , Baboldashti, Nasim Zargar, Hakimi, Osnat , Snelling, Sarah , Morrey, Mark E. , Mouthuy, Pierre‐Alexis , Price, Andrew James , Carr, Andrew Jonathan

Mayo Clinic

Regenerative Medicine | September 2, 2013 | Volume: 8 | Issue: 5 | Pages: 613-630

10.2217/rme.13.55 | PMID 23998754 Get It